IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option
Travere Therapeutics
About IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option
Listeners can expect to learn about: • The disease burden and underlying pathophysiology of IgA nephropathy, including the role of endothelin and angiotensin in disease progression • The current IgAN treatment landscape • The response to sparsentan, a dual endothelin angiotensin receptor antagonist, in patients with IgA nephropathy in the phase 3 PROTECT trial
- Publisher
- Travere Therapeutics
- Category
- education · science
- Language
- en
- Explicit
- No
- First episode
- 7 May 2024
- Latest episode
- 7 May 2024
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.